Squarepoint Ops LLC Purchases 28,662 Shares of Delcath Systems, Inc. (NASDAQ:DCTH)

Squarepoint Ops LLC lifted its position in Delcath Systems, Inc. (NASDAQ:DCTH - Free Report) by 56.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 79,537 shares of the company's stock after buying an additional 28,662 shares during the quarter. Squarepoint Ops LLC owned about 0.25% of Delcath Systems worth $958,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Quarry LP acquired a new stake in shares of Delcath Systems during the 4th quarter worth about $34,000. Quantbot Technologies LP bought a new stake in shares of Delcath Systems during the 4th quarter valued at approximately $66,000. Graham Capital Management L.P. bought a new stake in shares of Delcath Systems during the 4th quarter valued at approximately $123,000. Private Advisor Group LLC bought a new stake in Delcath Systems during the 4th quarter worth approximately $153,000. Finally, Charles Schwab Investment Management Inc. bought a new stake in Delcath Systems during the 4th quarter worth approximately $156,000. 61.12% of the stock is owned by institutional investors.

Delcath Systems Stock Up 3.0%

NASDAQ:DCTH traded up $0.49 during mid-day trading on Thursday, hitting $16.87. 410,173 shares of the stock traded hands, compared to its average volume of 380,053. Delcath Systems, Inc. has a 12-month low of $6.42 and a 12-month high of $18.23. The company has a market cap of $587.51 million, a PE ratio of -12.50 and a beta of 0.95. The business's 50-day moving average price is $13.56 and its 200 day moving average price is $13.36.

Delcath Systems (NASDAQ:DCTH - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported $0.03 earnings per share for the quarter, missing analysts' consensus estimates of $0.10 by ($0.07). Delcath Systems had a negative return on equity of 338.16% and a negative net margin of 150.70%. The business had revenue of $19.80 million during the quarter, compared to the consensus estimate of $16.83 million. Analysts anticipate that Delcath Systems, Inc. will post -0.79 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on DCTH. HC Wainwright reissued a "buy" rating and set a $29.00 target price (up from $24.00) on shares of Delcath Systems in a research note on Friday, May 23rd. Wall Street Zen downgraded shares of Delcath Systems from a "strong-buy" rating to a "buy" rating in a report on Sunday. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus target price of $24.00.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.